RxDoctor Payments Data

Lisa Mogelnicki, DPM

Podiatrist · Tulsa, OKNPI 1689967739

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,423 of the $2,258 with a category attached, or 63.0%. 12 manufacturers reported payments, led by Stryker at 52.9% of the total. Reporting peaked in 2024 at $1,159 and has fallen 90.1% since, to $115 in 2025.

$2,258in general payments, 2019–2025

Across 43 payments — averaging $52.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$1K
  • Trice Medical, Inc.$340
  • Smith+Nephew$225
  • Johnson & Johnson$123
  • Tenex Health Inc.$107
  • Organogenesis Inc.$65
  • plus $205 from 6 others

What the payments were for

  • Travel & lodging$83537%
  • Food & beverage$1,42363%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,258 in reported general payments places this provider in the 60th percentile of 54 podiatrist providers in Oklahoma.

See all podiatrist providers in Oklahoma

Medicare billing

Part B allowed, 2024
$160,539
Medicare patients
361
Services billed
2,309

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.15$9,145
Terbinafine Hcl119$1,158
Nabumetone79$1,016
Doxycycline Hyclate183$953
Ciclopirox30$888
Cyanocobalamin InjectionCyanocobalamin (Vitamin B-12)31$710
Gabapentin136$670
Ketoconazole49$638
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav60$471
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen51$381
Clindamycin Hcl43$351
Methylprednisolone38$335
Ciprofloxacin Hcl48$327
Duloxetine Hcl11$314
Celecoxib30$269

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$225$9,14515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 54 podiatrist providers in Oklahoma.

Other podiatrist in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →